RINVOQ

Medicinal product

(Invented) name

RINVOQ

Active substance (s)

Upadacitinibas

Strength

30 mg

Pharmaceutical form

pailginto atpalaidavimo tabletės

Route (s) of administration

vartoti per burną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L04AF03, upadacitinib

Marketing authorisation holder

AbbVie Deutschland GmbH & Co. KG , Vokietija

Date of authorisation

2019-12-16

Date of renewal

Documents

Rinvoq paciento kortele.pdf

Rinvoq mokomoji medziaga sveikatos prieziuros specialistams.pdf

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Prolonged-release tablet	1 vnt.
Upadacitinibas	30 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
107197	93301	1093301	lizdinė plokštelė	N28		Receptinis	EU/1/19/1404/006	Tiekiama	-	-	No	-	-
107199	93303	1093303	buteliukas	N30		Receptinis	EU/1/19/1404/007	Netiekiama	-	-	No	-	-
107200	93304	1093304	buteliukas	N90 (3×30)		Receptinis	EU/1/19/1404/008	Netiekiama	-	-	No	-	-
107198	93302	1093302	lizdinė plokštelė	N98 (2×49)		Receptinis	EU/1/19/1404/009	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2019-12-16	Registruotas